Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor segment discussing their recently granted India Patent No. 562,919. The patent, titled "Thailanstatin Analogs," covers the company's PH1 payload, proprietary cleavable and non-cleavable linkers, and ADC technology for cancer treatment applications.
The segment features CEO Abizer Gaslightwala explaining the significance of this patent protection for their immuno-oncology antibody drug conjugates (ADCs) technology platform.
Akari Therapeutics (Nasdaq: AKTX), una società biotecnologica nel campo oncologico, ha pubblicato un segmento Virtual Investor in cui discute del recente rilascio del Brevetto Indiano n. 562.919. Il brevetto, intitolato "Analoghi di Thailanstatin", protegge il payload PH1 dell'azienda, i linker proprietari cleavabili e non cleavabili, e la tecnologia ADC per applicazioni nel trattamento del cancro.
Nel segmento, il CEO Abizer Gaslightwala spiega l'importanza di questa protezione brevettuale per la loro piattaforma tecnologica di coniugati anticorpo-farmaco (ADC) in immuno-oncologia.
Akari Therapeutics (Nasdaq: AKTX), una empresa biotecnológica oncológica, ha lanzado un segmento Virtual Investor en el que discuten sobre la recientemente concedida Patente India No. 562,919. La patente, titulada "Análogos de Thailanstatin", cubre el payload PH1 de la compañía, los enlaces propietarios cleavables y no cleavables, y la tecnología ADC para aplicaciones en el tratamiento del cáncer.
El segmento presenta al CEO Abizer Gaslightwala explicando la importancia de esta protección de patente para su plataforma tecnológica de conjugados anticuerpo-fármaco (ADC) en inmuno-oncología.
Akari Therapeutics (Nasdaq: AKTX)는 최근 부여된 인도 특허 번호 562,919에 대해 논의하는 Virtual Investor 세그먼트를 발표한 종양학 생명공학 회사입니다. "Thailanstatin 유사체"라는 제목의 이 특허는 회사의 PH1 페이로드, 독점적인 가수분해성 및 비가수분해성 링커, 그리고 암 치료용 ADC 기술을 포함합니다.
이 세그먼트에서는 CEO Abizer Gaslightwala가 이 특허 보호가 면역항암 항체-약물 접합체(ADC) 기술 플랫폼에 갖는 중요성을 설명합니다.
Akari Therapeutics (Nasdaq : AKTX), une société de biotechnologie en oncologie, a publié un segment Virtual Investor discutant de leur brevet indien n° 562,919 récemment accordé. Le brevet, intitulé « Analogues de Thailanstatin », couvre le payload PH1 de la société, des linkers propriétaires clivables et non clivables, ainsi que la technologie ADC pour les applications de traitement du cancer.
Le segment présente le PDG Abizer Gaslightwala expliquant l’importance de cette protection par brevet pour leur plateforme technologique d’anticorps conjugués à des médicaments (ADC) en immuno-oncologie.
Akari Therapeutics (Nasdaq: AKTX), ein biotechnologisches Unternehmen im Bereich Onkologie, hat einen Virtual Investor-Segment veröffentlicht, in dem die kürzlich erteilte Indische Patentschrift Nr. 562.919 besprochen wird. Das Patent mit dem Titel "Thailanstatin-Analoga" umfasst den firmeneigenen PH1-Nutzlast, proprietäre cleavable und nicht-cleavable Linker sowie die ADC-Technologie für Krebsbehandlungsanwendungen.
Im Segment erläutert CEO Abizer Gaslightwala die Bedeutung dieses Patentschutzes für ihre Plattform der immunonkologischen Antikörper-Wirkstoff-Konjugate (ADCs).
- Patent protection secured in India for PH1 payload and ADC technology
- Technology has potential applications across multiple cancer targets
- None.
Access the “What This Means” segment here
BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced it recently participated in a Virtual Investor “What This Means” segment.
For the segment, Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed the Company’s recently issued India Patent No. 562,919 titled, “Thailanstatin Analogs,” covering claims for its potent immuno-oncology PH1 payload, proprietary non-cleavable and cleavable linkers and ADC technology which has applications across various cancer targets.
The ”What This Means” segment is now available here.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome inhibitor designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing inhibition has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. Using this novel payload, Akari has the ability to generate multiple ADC molecules based on the desired application to a range of cancer targets of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
What patent did Akari Therapeutics (AKTX) receive in India?
What technology is covered by AKTX's new India patent?
Who is the CEO of Akari Therapeutics discussing the India patent?
What type of company is Akari Therapeutics (AKTX)?
